Portal Instruments

Portal Instruments, founded in 2012 and headquartered in Cambridge, Massachusetts, is a private, pre-revenue platform company focused on revolutionizing the delivery of injectable biologics. The company has developed two core technologies: the PRIME needle-free injector, which delivers medication via a high-speed, hair-thin liquid stream, and the PRIME Nexus, a smart, reusable electromechanical autoinjector. Portal operates as a B2B partner for biopharmaceutical companies, aiming to integrate its devices as part of combination products to enhance patient experience and provide lifecycle management solutions for high-value therapeutics. Recent milestones include a multi-million-dollar development agreement with an undisclosed biotech and a collaborative study published with Regeneron.

PRIME platform featuring two core technologies: 1) a needle-free injector that delivers high-viscosity biologics via a high-speed, hair-thin liquid stream, and 2) the PRIME Nexus, a smart, reusable electromechanical autoinjector with programmable injection profiles for needle-based delivery.

Portal competes with large, established drug delivery companies like West Pharmaceutical Services, SHL Medical, and Ypsomed, which offer a wide range of autoinjectors and pen devices. It also faces competition from other needle-free technology startups (e.g., PharmaJet, Injex). Its differentiation lies in specifically targeting high-viscosity biologics and offering both needle-free and smart reusable needle-based options from a single platform.